PFECL.SN
PFIZER INC News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 6,
"returned": 6,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "041eadb4-d5f2-4e31-afe1-27b0fa1cf62c",
"title": "Pfizer Inc. (PFE) Inks $6 Billion Cancer Drug Licensing Agreement with China’s 3SBio",
"description": "On May 19, Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at approximately $6 billion with Chinese biopharmaceutical firm 3SBio Inc.",
"keywords": "",
"snippet": "Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!\n\nMy #...",
"url": "https://www.insidermonkey.com/blog/pfizer-inc-pfe-inks-6-billion-cancer-drug-licensing-agreement-with-chinas-3sbio-1536942/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/09/20100407/PFE-insidermonkey-1695218644644.jpg",
"language": "en",
"published_at": "2025-05-20T03:58:05.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFECL.SN",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 64.25279,
"sentiment_score": -0.296,
"highlights": [
{
"highlight": "<em>Pfizer</em> <em>Inc</em>. (PFE) Inks $6 Billion Cancer Drug Licensing Agreement with China’s 3SBio",
"sentiment": -0.296,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "f818ff6a-922d-42fe-9e42-8ac47ce6399f",
"title": "Pfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal - Pfizer (NYSE:PFE)",
"description": "Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody SSGJ-707.",
"keywords": "",
"snippet": "Pfizer Inc. PFE announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.‘s bispecific antibody SSGJ-707 in a deal potentially w...",
"url": "https://www.benzinga.com/general/health-care/25/05/45510221/pfizer-secures-global-rights-to-chinas-3sbios-cancer-drug-in-6-billion-deal",
"image_url": "https://cdn.benzinga.com/files/images/story/2025/05/19/Logo-Pfizer-Inc--Is-An-American-Multinat.jpeg?width=1200&height=800&fit=crop",
"language": "en",
"published_at": "2025-05-20T03:55:56.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFECL.SN",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 46.375725,
"sentiment_score": 0.18805,
"highlights": [
{
"highlight": "<em>Pfizer</em> <em>Inc</em>. PFE announ[+316 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em> will also make a $100 mi[+85 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The transaction gives <em>Pfizer</em> ma[+275 characters]",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em> Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal - <em>Pfizer</em> (NYSE:PFE)",
"sentiment": -0.4767,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "b6865050-9359-4a32-b89e-34e23d7e66c9",
"title": "世界の禁煙及びニコチン除去製品市場は、2031年までに547億米ドルに達し、年平均成長率（CAGR）10.6％で成長する見込み",
"description": "",
"keywords": "世界の禁煙及びニコチン除去製品市場は、2031年までに547億米ドルに達し、年平均成長率（CAGR）10.6％で成長する見込み, Panorama Data Insights Ltd., プレスリリース, ニュースリリース, 配信, 代行, DreamNews, ドリームニュース",
"snippet": "この市場の成長は、主に禁煙支援製品に対する需要の増加と、健康意識の向上が背景にあります。本報告では、禁煙及?...",
"url": "https://www.dreamnews.jp/press/0000320964/",
"image_url": "https://www.dreamnews.jp//?action_Image=1&p=0000320964&id=bodyimage1",
"language": "ja",
"published_at": "2025-05-20T01:30:00.000000Z",
"source": "dreamnews.jp",
"relevance_score": null,
"entities": [
{
"symbol": "PFECL.SN",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 7.858395,
"sentiment_score": null,
"highlights": [
{
"highlight": "● <em>Pfizer</em> <em>Inc</em>● Brit[+531 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "c24caf0e-95e2-42c8-ad5e-c386d50fa1dd",
"title": "Iterum Therapeutics Announces Extension of Term of Promissory Note | ITRM Stock News",
"description": "Iterum Therapeutics (ITRM) and Pfizer agree to extend a $20M debt payment deadline to October 2029. The interest rate on the debt will increase from 8%",
"keywords": "GuruFocus, Article, News, GuruFocus News, ITRM",
"snippet": "Iterum Therapeutics (ITRM, Financial) and Pfizer agree to extend a $20M debt payment deadline to October 2029.\n\nThe interest rate on the debt will increase from...",
"url": "https://www.gurufocus.com/news/2872861/iterum-therapeutics-announces-extension-of-term-of-promissory-note-itrm-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BFO6.png?20",
"language": "en",
"published_at": "2025-05-19T12:20:20.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFECL.SN",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 24.137018,
"sentiment_score": 0.6172,
"highlights": [
{
"highlight": "Iterum Therapeutics (ITRM, Financial) an[+257 characters]",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Iterum Therapeutics plc (NASDAQ: ITRM) h[+320 characters]",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "This change comes with some additional c[+199 characters]",
"sentiment": 0.5187,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "349f5869-9aeb-4d6b-a534-55675cf8d034",
"title": "Iterum Therapeutics Announces Extension of Term of Promissory Note",
"description": "DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc ( ITRM) (the ”Company” or ”Iterum”), a company focused on delivering next",
"keywords": "GuruFocus, Article, News, Marketwired, ITRM",
"snippet": "DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc ( ITRM) (the “Company” or “Iterum”), a company focused on delivering next g...",
"url": "https://www.gurufocus.com/news/2872747/iterum-therapeutics-announces-extension-of-term-of-promissory-note",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-19T12:00:05.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFECL.SN",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 18.440237,
"sentiment_score": 0.59282,
"highlights": [
{
"highlight": "DUBLIN and CHICAGO, May 19, 2025 (GLOBE [+305 characters]",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "(“<em>Pfizer</em>”) has agreed to ex[+102 characters]",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "“We are very pleased to announce that [+288 characters]",
"sentiment": 0.8739,
"highlighted_in": "main_text"
},
{
"highlight": "Pursuant to the license agreement entere[+349 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "The Company had the option to deliver no[+189 characters]",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "After receiving FDA approval for ORLYNVA[+278 characters]",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "On May 13, 2025, the Company and ITIL en[+269 characters]",
"sentiment": 0.8316,
"highlighted_in": "main_text"
},
{
"highlight": "ITIL also agreed that it would not, dire[+319 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
},
{
"highlight": "specified exceptions (including liens se[+96 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "ITIL also agreed to pay <em>Pfizer</em> [+55 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "6d0127da-f16a-4313-983a-6c0c98366afb",
"title": "Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny - Novavax (NASDAQ:NVAX), BioNTech (NASDAQ:BNTX)",
"description": "The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions that increase risk of severe illness.",
"keywords": "",
"snippet": "The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.’s NVAX COVID-19 vaccine, restricting its use to people 65 and older and tho...",
"url": "https://www.benzinga.com/government/regulations/25/05/45488265/novavax-wins-limited-fda-nod-for-covid-shot-cleared-only-for-seniors-high-risk-groups-amid",
"image_url": "https://cdn.benzinga.com/files/images/story/2025/05/19/Covid-Mask-shutterstock-1678274461.jpeg?width=1200&height=800&fit=crop",
"language": "en",
"published_at": "2025-05-19T08:39:34.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFECL.SN",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 21.042744,
"sentiment_score": -0.1591,
"highlights": [
{
"highlight": "What Happened: The decision follows a si[+209 characters]",
"sentiment": -0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "In the SHIELD-Utah study, Novavax recipi[+101 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "PFECL.SN",
"total_documents": 6,
"sentiment_avg": 0.18859400153160094
}
]
}
Other details
Exchange
- Santiago Stock Exchange
- equity
- N/A
- cl